A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of one
or more doses of AP30663 for cardioversion in adult participants with AF.